Wall Street Researcher



Ohio State Installs Ultra-Sheer Technologies

Shareholder Update – Record March 2022


These shares have bottomed recently on light volume. The 200 day M/A of $2.41 could be tested to the upside  soon. Average daily volume is 31,127 shares for the same 200 day period .

A superior management team is driving these shares higher discovering new uses for their medical device and achieveing record sales for March 2022 – Ultra Shear Tech Platform

We feel that a BUYING OPPORTUNITY is now at hand . All serious investors must place these shares on their BUY LIST and watch carefully for an UPSIDE BREAKOUT

Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC Cell :    516 – 455-7662 – EMAIL – gzplumtree@gmail.com  WATCH THIS MOST RECENT INVESTOR  VIDEO WITH PRESSURE BIOSCIENCE CEO RIC SCHUMACHER  


Pressure BioSciences Updates Stakeholders with Solid Progress on Key 2022 Goals: UST Commercial Release, Major Revenue Increase, Continued Financial Position Improvement, and Planned Uplist to National Market

Company Reports Record Instrument Orders in March, Expands BaroFold Platform Services, Builds Strong Demand for Initial UST Tolling Services, and Prepares Foundation for Uplisting

SOUTH EASTON, MA / ACCESSWIRE / March 17, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today updated stakeholders on the Company’s key 2022 goals. The Company believes these goals are attainable in the current fiscal year and that their achievement will put PBI on a rapid path to sustained growth, value increase, and profitability.
Mr. John B. Hollister, Director of Marketing and Sales at PBI, commented: “The 2020 pandemic year was very challenging for PBI. With a majority of our customers being academic and industrial laboratories, many were actually closed for much of 2020. Fortunately, most reopened in early 2021, which resulted in a return of strong product revenue for all of FY 2021. With continued laboratory openings in late 2021 and early 2022, and strongly renewed interest in PBI’s innovative product line, we are pleased to report the receipt of more instrument orders in the month of March 2022 than in any single calendar month in our history. We believe this strong demand trend will continue throughout 2022, and beyond.”
Mr. Richard T. Schumacher, President and CEO of PBI added: “In addition to the record number of instrument orders for a month, interest and engagement with our enabling BaroFold Platform protein refolding services has grown significantly over the past few months. We have also made measurable progress thus far in Q1 2022 in preparing for the commercialization of our revolutionary Ultra Shear Technology™ (UST™) Platform. Of particular note, we have significantly improved our balance sheet and solidified the foundation for our planned uplisting from the OTC Markets to a national exchange before year’s end. We have an exciting year ahead: we are prepared and ready for the challenge.”
A progress update on the Company’s four key 2022 goals:
Achieve Significant FY 2022 Revenue Increase

  • Record monthly instrument sales reported for March 2022. We expect interest and upward trend to continue.
  • PBI Agrochem sales started slowly pending planned assets acquisition. We expect strong Q2 2022 sales.
  • Discussions with key pharma groups expected to lead to significant BaroFold services contracts.

Ultra Shear Technology (UST) Platform Commercialization

  • First commercial system (“BaroShear MAX”) successfully installed at The Ohio State University (January).
  • Gala unveiling for major global food/beverage companies planned for May/June 2022.
  • East and west coast UST tolling sites (“fee for service”) expected to be operational by Q4 2022.
  • UST contracts expected to be signed with cosmetics, nutraceutical, and agrochem customers prior to Q4 2022.
  • Initial build of UST systems to be complete by year-end for 2023 placements under lease/license agreements.

Strengthen Financial Position

  • Dramatic improvements to debt structure nearly complete.
  • 80% of current loan debt has agreed to convert to equity upon uplist. Half of remaining loan debt expected to follow.

Uplist to NASDAQ or NYSE

  • A plan to meet requirements of NASDAQ/NYSE to qualify for 2022 uplisting developed and executing smoothly.

Mr. Jeffrey N. Peterson, PBI’s Board Chairman, provided a broader context: “Our team has performed admirably in challenging circumstances, to build strong growth in interest, trials, and results around each of our technology platforms. We are especially pleased with our excellent progress in resolving debt and accrued expense balances and consequent strengthening of our balance sheet in preparation for our UST services and licensing launch, our planned agrochemical company assets acquisition, and a new trajectory of accretive growth, all in preparation for the completion of our long-planned NASDAQ or NYSE uplisting. We thank our loyal investors for their strong multi-year support, as we zero in on our expected transition to profitability in 2023.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Pressure BioSciences PBIO OTCQB In Spotlight

COLUMBUS, Ohio—Food processing companies looking for innovative new ways to preserve clean-label liquid food without artificial preservatives will soon have a new option to do so thanks to new technology being developed at The Ohio State University College of Food, Agricultural, and Environmental Sciences (CFAES). Read More


A recent press release by Pressure BioSciences Inc. OTCQBPBIO announcing a development in its cannabidiol (CBD) research program seems to have given industry watchers an indication of the company’s future.


Pressure BioSciences, a player in the development and sale of broadly enabling, pressure-based systems with applications across multiple industries, including nutraceuticals, pharmaceuticals, and biotechnology, has set its sights on being a dominant force in many of these industries. A recent expansion drive appears to support this intention

A New CBD Manufacturing Technology?

Pressure BioSciences Inc. (PBI) revealed in a press release that hemp-derived CBD processed with its patented Ultra Shear Technology™ (UST™) platform produced high-quality, water-soluble nanoemulsions of CBD oil in water. The technology has now demonstrated visual and analytical stability 18 months after production and baseline testing.

From all indications, PBI feels that this revelation is welcome news and a game-changer for CBD and the rest of the cannabinoid industry. For some years now, a significant obstacle to CBD’s commercial advancement has been its insolubility in water and poor absorption (bioavailability) by the human body.

The World Health Organization (WHO) estimates that as little as 6% of CBD is absorbed via current oral delivery routes. Thus, most ingested CBD is wasted, passing through the body without being absorbed.

This impediment engendered interest in the development a truly water-soluble CBD to deliver efficient dosing, absorption, bioavailability and benefit from CBD products — foods, beverages,cosmetics, and therapeutics. PBI seems to have surmounted that problem.

For years, CBD oil has been studied for its potential ability to ease the symptoms of many health conditions — including neurological disorders. It is a widely popular therapeutic for the relief of anxiety, depression and PTSD, as well as chronic inflammatory and neuropathic pain.

CBD has been approved by the U.S. Food and Drug Administration (FDA) to control epileptic seizures in Lennox-Gastaut syndrome and Dravet syndrome.

Early research suggests that CBD reduces spasticity in multiple sclerosis and may lessen the severity of neurological symptoms associated with Alzheimer’s DiseaseParkinson’s disease and schizophrenia. CBD is under investigation as a palliative adjunctive therapy in cancer.

A Growth Opportunity For PBI?

Dr. Alexander V. Lazarev, chief science officer of PBI, explained that “nanoemulsions, liposomes and solid lipid nanoparticles present many exciting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of oil droplets or particles, the better the stability and bioavailability of these preparations.”

Commercial UST System

Droplet size is a key determinant of accurate dosing and absorption, and an exciting benefit of the UST technology platform.  According to Gary B. Smejkal, a senior research scientist at PBI, “the intense fluid shearing in UST progressively decreases oil droplet size with each cycle, making the method highly tunable.” The platform can produce CBD nanoemulsions of uniform 30 to 40 nm droplet sizes that are stable at room temperature for at least 18 months, Smejkal added.

Giving a forecast of the breakthrough technology, John B. Hollister, director of sales and marketing at PBI, revealed that it offers the potential to revolutionize the rapidly growing cannabis market in food, beverages, and therapeutics.

Hollister was optimistic that PBI’s historic stability milestone positions PBI for rapid customer adoption of the UST nanoemulsion system upon commercial release, planned for the second half of 2022.

To view a short video of PBI’s innovative UST platform for the preparation of CBD nanoemulsions, click here.

Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN  or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN  or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. Writer charges PBIO a fee of $950 per month . All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly